

Cecilia Garlanda

Discloser Identifier: 909177 **Disclosure Purpose:** Review - Humoral Innate Immunity and Acute Phase Proteins at the time of COVID-19

Summary of Interests

Intellectual Property

Type	Is Licensed	Interest Held By						
Other Intellectual Property - Royalties related to the sale of reagents (monoclonal antibodies) to various companies	-	Self						
<i>Description:</i> Royalties related to the sale of reagents (monoclonal, polyclonal antibodies) to various companies <i>Additional Information:</i>								
Patent - Patent - PTX3 as prognostic marker in Covid-19	-	Self						
<i>Description:</i> Patent - PTX3 as prognostic marker in Covid-19 <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> ITA <i>Licensees:</i>								
<i>Patent Number:</i> european patent 201821816 <i>Patent Holder:</i> Current Institution								
<table border="1"><thead><tr><th>Licensee</th><th>Title</th><th>Date</th></tr></thead><tbody><tr><td>DiaSorin Inc.</td><td>PTX3 as prognostic marker in Covid-19</td><td>11/06/2021</td></tr></tbody></table>	Licensee	Title	Date	DiaSorin Inc.	PTX3 as prognostic marker in Covid-19	11/06/2021		
Licensee	Title	Date						
DiaSorin Inc.	PTX3 as prognostic marker in Covid-19	11/06/2021						
<i>Additional Information:</i> Humanitas holds the IP , Cecilia Garlanda is one of the inventors and will get royalties if the assay is eventually approved								

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Humoral Innate Immunity and Acute Phase Proteins at the time of COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 545595 **Disclosure Purpose:** Review - Humoral Innate Immunity and Acute Phase Proteins at the time of COVID-19

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie Biotherapeutics	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> seminar <i>Additional Information:</i> Seminar and discussion related to immunotherapy and vaccines</p>		
AstraZeneca	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> advisory boards <i>Additional Information:</i> in 2021 I participated in advisory boards related to vaccines at a national or international level</p>		
Fondazione Internazionale Menarini	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> seminar <i>Additional Information:</i></p>		
GlaxoSmithKline	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i></p>		
Humanitas University	Employment	Self
<p><i>Title:</i> Scientific Director <i>Additional Information:</i> Royalties related to the sale of reagents (monoclonal and polyclonal antibodies) to various companies to various companies in the years 2018-2020</p> <p style="text-align: right;"><i>Position Description:</i></p>		
Janssen Pharmaceuticals	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> 1/2 day <i>Additional Information:</i></p>		
PerkinElmer Inc	Stock	Self
<p><i>Additional Information:</i> 2,200 shares from Biologend merger. Sold in 2021 and 2022</p>		
Pfizer	Consultant	Self

Entity	Type	Interest Held By
<p><i>Category:</i> Consultant <i>Description:</i> lecture <i>Additional Information:</i> one day, lecture</p>		

Intellectual Property

Type	Is Licensed	Interest Held By						
Patent - PTX3 as prognostic marker in Covid-19	-	Self						
<p><i>Description:</i> PTX3 as prognostic marker in Covid-19 <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> ITA <i>Licensees:</i></p> <p><i>Patent Number:</i> european patent 201821816 <i>Patent Holder:</i> Current Institution</p> <table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>DiaSorin Inc.</td> <td>PTX3 as prognostic marker in Covid-19</td> <td>11/06/2021</td> </tr> </tbody> </table> <p><i>Additional Information:</i> Humanitas holds the IP , Alberto Mantovani is one of the inventors and will get royalties if the assay is eventually approved</p>			Licensee	Title	Date	DiaSorin Inc.	PTX3 as prognostic marker in Covid-19	11/06/2021
Licensee	Title	Date						
DiaSorin Inc.	PTX3 as prognostic marker in Covid-19	11/06/2021						

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Humoral Innate Immunity and Acute Phase Proteins

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Cecilia Garlanda

Certification

I certify that the information provided in this disclosure is complete and accurate.